Byondis Showcases Novel ADC Technology at American Society for Cancer Research Meeting
Byondis B.V., a biopharmaceutical company based in the Netherlands, is presenting its innovative antibody-drug conjugate (ADC) technology platforms at the American Society for Cancer Research (AACR) Annual Meeting 2026 in San Diego, California. The company is highlighting two state-of-the-art platforms: an antifolate linker-drug platform and a phosphonate linker-drug platform. These platforms are designed to address limitations in current cancer treatments, such as acquired resistance and lack of tumor specificity. The antifolate platform offers a differentiated mechanism of action to overcome resistance, while the phosphonate platform activates gamma delta T cells for targeted tumor cell killing. Byondis aims to provide new treatment options for patients who do not respond to existing immune therapies. 
